BG Medicine, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. The company reported net loss for the second quarter of 2015 of $2.0 million, a 6% improvement from the $2.2 million net loss reported in the second quarter of 2014, on total revenues of $0.5 million in the second quarter of 2015 versus total revenues of $0.8 million in the second quarter of 2014. Net loss per basic and diluted share in the second quarter of 2015 was $0.23 as compared to $0.26 in 2014. Operating cash burn decreased by $1.8 million, a 68% decrease, to $827 thousand compared to $2.6 million in 2014. Loss from operations was $1.4 million compared to $2 million for the same period of last year.
For the six months ended June 30, 2015, the company reported net loss of $3.4 million, a 22% improvement from the $4.3 million net loss reported for the six months ended June 30, 2014, on total revenues of $0.9 million versus total revenues of $1.5 million in the first six months of 2014. Net loss per basic and diluted share for the first six months of 2015 was $0.39 as compared to $0.56 in the first six months of 2014. Operating cash burn declined by $2.8 million, a 56% decrease, to $2.2 million compared to $5.0 million in 2014. Loss from operations was $2.7 million compared to $3.9 million for the same period of last year. Net cash flows from operating activities were $2.2 million compared to $5 million for the same period of last year.